| Clinical data | |
|---|---|
| Other names | MYCO005 |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen[1][2][3] |
MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][4][3][5]
It is a tryptamine derivative and an analogue of psilocin.[1][3] However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT2A receptor but also the serotonin 5-HT2B receptor, MYCO-005 does not bind to this receptor.[1][3] Activation of the serotonin 5-HT2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics.[6][7] Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.[1][3][5]
As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders.[1] It is being developed by Mydecine.[1][2] The exact chemical structure of MYCO-005 does not yet seem to have been disclosed.[1] However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues.[5][8]
A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...]